Nano-based eye drop: Topical and noninvasive therapy for ocular diseases
- PMID: 36773886
- DOI: 10.1016/j.addr.2023.114721
Nano-based eye drop: Topical and noninvasive therapy for ocular diseases
Abstract
Eye drops are the most accessible therapy for ocular diseases, while inevitably suffering from their lower bioavailability which highly restricts the treatment efficacy. The introduction of nanotechnology has attracted considerable interest as it has advantages over conventional ones such as prolonged ocular surface retention time and enhanced ocular barrier penetrating properties, and achieving higher bioavailability and improved treatment efficacy. This review describes various ocular diseases treated with eye drops as well as the physiological and anatomical ocular barriers faced with through drug administration. It also summarizes the recent advances regarding the utilization of nanotechnology in developing eye drops, and how to optimize the nanocarrier-based ocular drug delivery systems. The prospective future research directions for nano-based eye drops are also discussed here.
Keywords: Eye drops; Nanoparticles; Nanotechnology; Non-invasive.
Copyright © 2023. Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Nanotechnology-based non-invasive strategies in ocular therapeutics: Approaches, limitations to clinical translation, and safety concerns.Cont Lens Anterior Eye. 2025 Apr;48(2):102367. doi: 10.1016/j.clae.2025.102367. Epub 2025 Jan 9. Cont Lens Anterior Eye. 2025. PMID: 39794261 Review.
-
Applications of Nanotechnology-mediated Herbal Nanosystems for Ophthalmic Drug.Pharm Nanotechnol. 2024;12(3):229-250. doi: 10.2174/2211738511666230816090046. Pharm Nanotechnol. 2024. PMID: 37587812 Review.
-
Recent advances in ophthalmic preparations: Ocular barriers, dosage forms and routes of administration.Int J Pharm. 2021 Oct 25;608:121105. doi: 10.1016/j.ijpharm.2021.121105. Epub 2021 Sep 17. Int J Pharm. 2021. PMID: 34537269 Review.
-
Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases.J Control Release. 2023 Feb;354:465-488. doi: 10.1016/j.jconrel.2023.01.018. Epub 2023 Jan 19. J Control Release. 2023. PMID: 36642250 Review.
-
Application of lipid nanoparticles to ocular drug delivery.Expert Opin Drug Deliv. 2016 Dec;13(12):1743-1757. doi: 10.1080/17425247.2016.1201059. Epub 2016 Jun 24. Expert Opin Drug Deliv. 2016. PMID: 27291069 Review.
Cited by
-
Options for Topical Treatment of Oxidative Eye Diseases with a Special Focus on Retinopathies.Medicina (Kaunas). 2024 Feb 21;60(3):354. doi: 10.3390/medicina60030354. Medicina (Kaunas). 2024. PMID: 38541080 Free PMC article. Review.
-
An annular corneal microneedle patch for minimally invasive ophthalmic drug delivery.Sci Adv. 2025 Mar 7;11(10):eadv1661. doi: 10.1126/sciadv.adv1661. Epub 2025 Mar 7. Sci Adv. 2025. PMID: 40053577 Free PMC article.
-
Cyclic cell-penetrating peptide-engineered ceria nanoparticles for non-invasive alleviation of ultraviolet radiation-induced cataract.J Nanobiotechnology. 2025 May 7;23(1):337. doi: 10.1186/s12951-025-03402-1. J Nanobiotechnology. 2025. PMID: 40336002 Free PMC article.
-
Recent Achievements and Perspectives in Smart Nano-in-Micro Platforms for Ocular Disease Treatment.Int J Nanomedicine. 2025 Jun 17;20:7579-7612. doi: 10.2147/IJN.S518643. eCollection 2025. Int J Nanomedicine. 2025. PMID: 40546796 Free PMC article. Review.
-
Thermoresponsive antioxidant metal-free carbon nanodot hydrogel: An effective therapeutic approach for ocular surface disease.Sci Adv. 2025 Jul 25;11(30):eadt8775. doi: 10.1126/sciadv.adt8775. Epub 2025 Jul 25. Sci Adv. 2025. PMID: 40712015 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical